Treatment of AIDS-related lymphomas: Rituximab is beneficial even in severely immunosuppressed patients

AIDS

Volumn 26, Issue 4, 2012, Pages 457-464

  Wyen, Christoph ^a   Jensen, Björn ^b   Hentrich, Marcus ^c   Siehl, Jan ^d   Sabranski, Michael ^e   Esser, Stefan ^f   Gillor, Daniel ^a   Müller, Markus ^g   Van Lunzen, Jan ^h   Wolf, Timo ⁱ   Bogner, Johannes R ^j   Wasmuth, Jan C ^k   Christ, Hildegard ^a   Fätkenheuer, Gerd ^a   Hoffmann, Christian ^l,m  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Harlaching Hospital   (Germany)

^d Ärzteforum Seestrasse Medical Center   (Germany)

^e Ifi Institute for Interdisciplinary Medicine   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^h UNIVERSITY OF HAMBURG   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF BONN   (Germany)

^l IPM Study Center   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

AIDS related lymphoma; HIV; multicenter cohort study; rituximab

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACQUIRED IMMUNODEFICIENCY SYNDROME RELATED LYMPHOMA; ADULT; AGED; AIDS RELATED LYMPHOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; FEMALE; GERMANY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; TREATMENT OUTCOME;

EID: 84857061021     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f30fa     Document Type: Article

References (27)

1. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416-422.
2. Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47:1822-1829. (Pubitemid 44649767)
3. Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, et al. Outcome in patients with nonhodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38:142-144. (Pubitemid 38045886)
4. Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23:2029-2037.
5. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130. (Pubitemid 40347381)
6. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296. (Pubitemid 30459587)
7. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDSdefining conditions are created equal. Clin Infect Dis 2009; 48:1138-1151.
8. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOPplus rituximab in patients with HIVassociated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123-4128. (Pubitemid 46622288)
9. Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood 2006; 107:3014-3015.
10. Ribera JM, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008; 140:411-419.
11. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105:1891-1897. (Pubitemid 40731769)
12. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002; 159:149-153.
13. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008-3016.
14. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543. (Pubitemid 41208563)
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
16. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87:495-508. (Pubitemid 26030305)
17. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007; 12:931-939. (Pubitemid 47492562)
18. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active antiretroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112:909-915. (Pubitemid 32322915)
19. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22:1491-1500. (Pubitemid 41103632)
20. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, et al. Acquired immunodeficiency syndromerelated lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer 2006; 106:1560-1568.
21. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, Hamouda O. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79-87.
22. Bonnet F, Balestre E, Thiebaut R, Morlat P, Pellegrin JL, Neau D, Dabis F. Factors associated with the occurrence of AIDSrelated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis 2006; 42:411-417. (Pubitemid 43122322)
23. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17:1521-1529. (Pubitemid 36900553)
24. Lascaux AS, Hemery F, Goujard C, Lesprit P, Delfraissy JF, Sobel A, et al. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses 2005; 21:214-220. (Pubitemid 40478229)
25. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A prognostic index for systemic AIDSrelated non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265-273.
26. Hoffmann C, Tiemann M, Schrader C, Janssen D, Wolf E, Vierbuchen M, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762-1769. (Pubitemid 41208592)
27. Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a populationbased case series in Sydney, Australia. HIV Med 2004; 5:377-384. (Pubitemid 39276337)